Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibandronate vs Alendronate Preference in Osteoporosis
NCT00327990Phase 4
Key facts
- Status
- Completed
- Start
- Apr 2005
- Primary completion
- Dec 2006
- Countries
- 1
- Sponsor
- GSK
- Modality
- Small Molecules
- Drugs
- ibandronate
- Conditions
- osteoporosis
01
Overview
Phase 4, randomised, open-label trial of ibandronate in osteoporosis (2 arms), sponsored by GSK. Primary endpoints: Percentage of patients falsely not diagnosed with osteoporosis and Patient preference for once monthly ibandronate or once weekly alendronate. Started Apr 2005; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Ibandronate then Alendronate
Patients receive monthly Ibandronate first, then switch to weekly Alendronate.
Alendronate then Ibandronate
Patients receive weekly Alendronate first, then switch to monthly Ibandronate.
03
Who it enrols
Women registered with a GP, without a prior history of osteoporosis, who are then screened and diagnosed with osteoporosis.
04
Endpoints
Primary
Percentage of patients falsely not diagnosed with osteoporosis
Patient preference for once monthly ibandronate or once weekly alendronate
Secondary
Safety and tolerance of both ibandronate and alendronate
Patient preference in reminder methods
Beyond the preview
Go deeper on NCT00327990.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00327990.